Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NDUFS8 | O00217 | 1/20 | 0.45 |
| ▸ | COXFA4 | O00483 | 1/20 | 0.45 |
| ▸ | NDUFAB1 | O14561 | 1/20 | 0.45 |
| ▸ | NDUFA1 | O15239 | 1/20 | 0.45 |
| ▸ | NDUFS4 | O43181 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080047 | 1.00 | MTNR1A (0.50) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL3089499 | 0.89 | MTNR1A (0.58) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL3089501 | 0.89 | MTNR1A (0.58) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL3080319 | 0.88 | PTGES (0.53) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL3080317 | 0.88 | PTGES (0.53) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL6650602 | 0.88 | MTNR1A (0.60) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL6650611 | 0.88 | MTNR1A (0.60) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL8212052 | 0.87 | EP300 (0.45) | MTNR1APTGES | |
| SCHEMBL3073003 | 0.87 | PTGES (0.52) | MTNR1APTGESALOX15TRPV1HDAC3 | |
| SCHEMBL3073002 | 0.87 | PTGES (0.52) | MTNR1APTGESALOX15TRPV1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267827-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-10-21 | — | — | US | disclosed |
| US-20100267827-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-10-21 | — | — | US | disclosed |
| US-20100267827-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2010-10-21 | — | — | US | disclosed |
| EP-2051958-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2009-04-29 | — | — | EP | disclosed |
| EP-1886990-A1 | Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders | Neuropharma S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| EP-1886990-A1 | Phenyl-prenyl-ether derivatives for the treatment of cognitive neurodegenerative or neuronal diseases or disorders | Neuropharma S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| WO-2008015241-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015241-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | NOSCIRA, S.A. (ES) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267827-A1 | PHENYL-PRENYL-ETHER DERIVATIVES FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS | PARK7, PSEN2, PSEN1 | MTNR1A 664/4885PTGES 175/4885ALOX15 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.